These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 23250663)

  • 1. Cardiovascular effects of anti-diabetic medications in type 2 diabetes mellitus.
    Singh S; Bhat J; Wang PH
    Curr Cardiol Rep; 2013 Jan; 15(1):327. PubMed ID: 23250663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cardiovascular safety of non-insulin anti-diabetic drugs. Scientific position statement of SEMERGEN].
    Prieto MÁ; Comas Samper JM; Escobar Cervantes C; Gasull Molinera V
    Semergen; 2014; 40(5):261-73. PubMed ID: 24882393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes.
    Zhang Z; Chen X; Lu P; Zhang J; Xu Y; He W; Li M; Zhang S; Jia J; Shao S; Xie J; Yang Y; Yu X
    Cardiovasc Diabetol; 2017 Mar; 16(1):31. PubMed ID: 28249585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
    Yandrapalli S; Jolly G; Horblitt A; Sanaani A; Aronow WS
    Postgrad Med; 2017 Nov; 129(8):811-821. PubMed ID: 28749197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus.
    Bolen S; Feldman L; Vassy J; Wilson L; Yeh HC; Marinopoulos S; Wiley C; Selvin E; Wilson R; Bass EB; Brancati FL
    Ann Intern Med; 2007 Sep; 147(6):386-99. PubMed ID: 17638715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular Effects of Glucose-lowering Therapies for Type 2 Diabetes: New Drugs in Perspective.
    Thompson PL; Davis TME
    Clin Ther; 2017 May; 39(5):1012-1025. PubMed ID: 27863704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)-TIMI 53 trial.
    Mosenzon O; Raz I; Scirica BM; Hirshberg B; Stahre CI; Steg PG; Davidson J; Ohman P; Price DL; Frederich B; Udell JA; Braunwald E; Bhatt DL
    Diabetes Metab Res Rev; 2013 Jul; 29(5):417-26. PubMed ID: 23564755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
    Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
    J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New approaches to treating type 2 diabetes mellitus in the elderly: role of incretin therapies.
    Abbatecola AM; Maggi S; Paolisso G
    Drugs Aging; 2008; 25(11):913-25. PubMed ID: 18947259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glitazones and alpha-glucosidase inhibitors as the second-line oral anti-diabetic agents added to metformin reduce cardiovascular risk in Type 2 diabetes patients: a nationwide cohort observational study.
    Chan CW; Yu CL; Lin JC; Hsieh YC; Lin CC; Hung CY; Li CH; Liao YC; Lo CP; Huang JL; Lin CH; Wu TJ
    Cardiovasc Diabetol; 2018 Jan; 17(1):20. PubMed ID: 29368615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes.
    Xu J; Rajaratnam R
    Cardiovasc Diabetol; 2017 Feb; 16(1):18. PubMed ID: 28148253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular safety of therapies for type 2 diabetes.
    Gupta P; White WB
    Expert Opin Drug Saf; 2017 Jan; 16(1):13-25. PubMed ID: 27652617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treating type 2 diabetes: how safe are current therapeutic agents?
    Philippe J; Raccah D
    Int J Clin Pract; 2009 Feb; 63(2):321-32. PubMed ID: 19196370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exogenous insulin administration and cardiovascular risk in non-insulin-dependent and insulin-dependent diabetes mellitus.
    Genuth S
    Ann Intern Med; 1996 Jan; 124(1 Pt 2):104-9. PubMed ID: 8554200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Glitazone - mailing no 1. In response to DMW 49/2007].
    Traut V
    Dtsch Med Wochenschr; 2008 Feb; 133(6):261; author reply 262-3. PubMed ID: 18236356
    [No Abstract]   [Full Text] [Related]  

  • 17. Fracture risk associated with common medications used in treating type 2 diabetes mellitus.
    Wolverton D; Blair MM
    Am J Health Syst Pharm; 2017 Aug; 74(15):1143-1151. PubMed ID: 28743778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Oral antidiabetic drugs. How to begin and combine without cardiovascular risk].
    Duarte R
    Rev Port Cardiol; 2013 Apr; 32 Suppl 1():15-24. PubMed ID: 23721975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second line therapy: type 2 diabetic subjects failing on metformin GLP-1/DPP-IV inhibitors versus sulphonylurea/insulin: for GLP-1/DPP-IV inhibitors.
    Kumar A
    Diabetes Metab Res Rev; 2012 Dec; 28 Suppl 2():21-5. PubMed ID: 23280862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cardiovascular effect of incretin-based therapies among type 2 diabetes: a systematic review and network meta-analysis.
    Wu S; Cipriani A; Yang Z; Yang J; Cai T; Xu Y; Quan X; Zhang Y; Chai S; Sun F; Zhan S
    Expert Opin Drug Saf; 2018 Mar; 17(3):243-249. PubMed ID: 29320889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.